Genomics/Genetics

Our technology portfolio

Genomic and genetic testing has become a key element to drug discovery and development and is emerging in clinical routine. We are offering state of the art technologies for exploratory testing as well as for clinical decision making through Medicover Genetics

Sequencing

Next-generation sequencing

  • Exome Sequencing
  • Targeted NGS
  • Custom Targeted NGS
  • cf-DNA analysis
  • RNA Exome Sequencing
  • Whole Transcriptopme Analysis
  • Noncoding RNA Analysis
  • DNA- / RNA-methylation
  • Cancer panels
  • Liquid biopsy approach

Single cell sequencing

Sanger sequencing

PCR

 

 

  • High-throughput RT-PCR
  • Droplet Digital PCR
  • Custom Droplet Digital PCR
  • MSRD RT-PCR
 

Microarray

 

 

  • comparative genomic hybridization
  • Gene expression
  • Genomic aberrations:
  • CNV, SNPs
  • DNA-methylation

NGS panels for exploratory testing

Commercially available panels

  • QIAGEN QIAseg Tumor Mutational Burden
    • Comprehensive panel, 486 genes
    • 27 MSI markers can be added
  • ILLUMINA TruSight Oncology 500
    • Pan-cancer panel
    • 523 genes for assessment of all DNA and RNA variant types, MSI and TMB
  • TWISTBIOSCIENCES Human Core Exome
    • Whole exam panel (33MB)

NGS panels for clinical testing

In cooperation with our partner NIPD we are offering certain predefined NGS panels

Pre-defined panels

  • Based on NIPD Genetics proven and novel technology
    • Launched 2015 for cff DNA analysis (Veracity®)
    • Proven clinical applicability and fidelity
  • Coverage of the most clinically relevant genes
  • Detection of multiple types of alterations for maximum diagnostic power
    • Single nucleotide variants (SNVs)
    • Insertions and deletions (INDELS)
    • Translocations
    • Copy number amplifications (CNAs)
  • Unrivalled accuracy >99.99% with a limit of detection (LOD) down to 0.1% for SNVs/INDELS and 1% for translocations
  • Superior Technology-Competitive Advantages
    • Proprietary form of in-solution hybridisation technology
    • Superior enrichment via custom long molecular probes (TACS)
    • State of the Art error-correction method
    • Novel enrichment methodology for circulating tumor DNA
    • High-sensitivity INDEL detection  
    • Multi-engine copy number detection
    • Unique Cancer-Trace-Detection technology-a prognostic factor on disease progression and outcome

NIPD PreSentia Hereditary Cancer Panel

  • 18 cancer specific panels
  • 1 pan cancer panel

NIPD ForeSentia Somatic Cancer Panel

  • 6 cancer specific panels
  • 1 pan cancer panel
  • 5 therapy associated panels
 

Customized solutions

  • Scalable Technology platform allows for rapid development of customized assays for any gene
  • Technology allows development of combined assays such as Liquid Biopsy and Tissue biopsy
  • Whole exome and whole genome sequencing
  • Methylation analysis (epigenetics)


nipd PRE-DEFINED ngs cancer panels FOR CLINICAL TESTING


HEREDITARY CANCER PANEL

Hereditary Cancer Pnael 1


SOMATIC CANCER PANEL

Somatic Cancer Panel 1

Single cell sequencing

Europe-wide 10X Genomics service provider with unique on-site services – from study design to reliable data

  • On-site GEM (Gel bead in Emulsion) generation and library preparation (10X Genomics Chromium Controller)
  • Sequencing and the full bioinformatics pipeline
  • Transformation of the data in an illustrative and understandable form
  • Explore cellular heterogeneity, novel targets, and biomarkers with combined gene expression, surface protein expression, or CRISPR edits
  • Analyse full length paired B-cell or T-cell receptors (V(D)J clonotypes) and antigen specificity
  • Analyse chromatin accessibility for a deeper understanding of gene regulatory mechanisms
10X Genomics 2


application examples

CONTACT US


Where to find us 

Lochhamer Str. 29A 82152 Planegg, Germany
Google Maps
Our Email

Write us an email.
Write us
Call Us

Mo-Fr, between 08:30-17:00 CET
+49-89-89557840
Call us
Scroll Up